214450 — PharmaResearch Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapHigh Flyer

Market Cap
KR₩7tn
Enterprise Value
KR₩7tn
Revenue
KR₩350bn

Annual income statement for PharmaResearch Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	108,746	154,083	194,759	261,011	350,115
Cost of Revenue
Gross Profit	72,896	108,333	141,513	190,258	251,237
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	76,571	102,434	133,954	171,873	224,519
Operating Profit	32,175	51,649	60,805	89,138	125,596
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	39,537	56,033	54,048	100,705	115,813
Provision for Income Taxes
Net Income After Taxes	32,452	46,824	43,434	77,265	88,943
Minority Interest
Net Income Before Extraordinary Items
Net Income	32,774	46,689	40,577	76,551	92,043
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	32,774	47,397	43,603	79,056	92,043
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3,587	4,766	4,534	7,711	8,976
Dividends per Share